"During the early stage, it's possible for people with dementia to live well by taking control of their health and wellness, ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer's disease ... more options and greater opportunity to have more time. Having multiple treatment options ...

Having multiple treatment options is the kind of advancement ... showed physical changes that happen in the brain due to Alzheimer’s disease. “Defining diseases by the biology has long been ...

A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Early detection is critical, as it offers patients and their families more time to manage the disease and explore treatment options. Alzheimer’s: A Growing Concern Alzheimer’s disease is a ...